RVP vs NVCR vs NKTR vs NNBR vs RCUS

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -12. 1%, compared to -92. 6% for Retractable Technologies, Inc. (RVP). Over 10 years, the gap is even starker: RCUS returned +49. 2% versus NNBR's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Retractable Technologies, Inc.

(RVP) is the lower-risk stock at 0. 72β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 199% more volatile than RVP relative to the S&P 500. On balance sheet safety, Retractable Technologies, Inc. (RVP) carries a lower debt/equity ratio of 1% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -66. 7% for Retractable Technologies, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NN, Inc.

(NNBR) is the more profitable company, earning -8. 1% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps -8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NNBR leads at -4. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 87.

3% to $33. 50.

In this comparison, RVP (1.

1% yield) pays a dividend. NVCR, NKTR, NNBR, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Retractable Technologies, Inc.

(RVP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72), 1. 1% yield). NN, Inc. (NNBR) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RVP: -70. 2%, NNBR: -75. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RVP (Healthcare) and NVCR (Healthcare) and NKTR (Healthcare) and NNBR (Industrials) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

RVP pays a dividend while NVCR, NKTR, NNBR, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.